RECRUITMENT OF PATIENTS

Age: 7-14 years
Diagnosis of TS following DSM-IV criteria
Informed consent by parents
No criteria for exclusion matched

Exacerbation according to parents

CONFIRMATION OF EXACERBATION

Evaluation of YGTSS by researcher
If YGTSS ≥ 40
Enter the Trial (t0)

Randomization, blinding, and treatment allocation

EXPERIMENTAL GROUP

Magnesium pidolate solution 0.5 mEq/kg/day
Pyroxidine alpha-ketoglutarate solution 2 mg/kg/day

CONTROL GROUP

Placebo: solution simulating Magnesium pidolate
Placebo: solution simulating Pyroxidine alpha-ketoglutarate

In both groups:
Concurrent medication permitted

<table>
<thead>
<tr>
<th></th>
<th>t0 (start, exacerbation)</th>
<th>YGTSS (≥40)</th>
<th>PET</th>
<th>PGWBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>t1</td>
<td>(15 days)</td>
<td>YGTSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t2</td>
<td>(30 days)</td>
<td>YGTSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t3</td>
<td>(60 days)</td>
<td>YGTSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t4</td>
<td>(90 days)</td>
<td>YGTSS</td>
<td>PE</td>
<td>PGWBI</td>
</tr>
</tbody>
</table>

DATA ANALYSIS

WITHDRAWAL OF PATIENTS: side effects or worsening